Publications by authors named "Leticia Mayor-Lopez"
Glioblastomas are highly resistant to radiation and chemotherapy. Currently, there are no effective therapies for this type of tumor. Signaling mechanisms initiated by PDGFR and IGF-1R are important in glioblastoma, and inhibition of the signal transduction pathways initiated by these receptors could be a useful alternative strategy for glioblastoma treatment.
View Article and Find Full Text PDFArticle Synopsis
- The study compares the effects of two Hsp90 inhibitors, 17-AAG and NVP-AUY922, on pancreatic and colorectal cancer cell lines.
- While some cell lines were resistant to 17-AAG, they showed sensitivity to NVP-AUY922, highlighting its potential as a more effective treatment.
- NVP-AUY922 not only works independently of the NQO1 enzyme but also enhances the effects of other chemotherapy drugs like gemcitabine and oxaliplatin.
Selumetinib (AZD6244, ARRY-142886) is a MEK1/2 inhibitor that has gained interest as an anti-tumour agent. We have determined the degree of sensitivity/resistance to Selumetinib in a panel of colorectal cancer cell lines using cell proliferation and soft agar assays. Sensitive cell lines underwent G1 arrest, whereas Selumetinib had no effect on the cell cycle of resistant cells.
View Article and Find Full Text PDF